| Authors: |
Lilly L; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Brown D; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Li N; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Drahos J; Vertex Pharmaceuticals Incorporated, Boston, MA, USA. jennifer_drahos@vrtx.com., Calvert M; Centre for Patient-Reported Outcomes Research, University of Birmingham, Birmingham, UK.; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.; NIHR Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK.; Birmingham Health Partners Centre for Regulatory Science and Innovation, Centre of Excellence in Regulatory Science and Innovation for Advanced Therapies (CERSI-AT), LifeArc Centre for Acceleration of Rare Disease Trials, University of Birmingham, Birmingham, UK., Levine L; Independent Consultant, Orange, CA, USA., Dongha N; Independent Consultant, London, UK., Pakbaz Z; Division of Hematology/Oncology, The University of California Irvine School of Medicine, Orange, CA, USA., Shah F; United Arab Emirates, Burjeel Medical City, Khalifa University, 7 Sick Cells, Abu Dhabi, Washington, DC, USA., Valentine A; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Franks B; Prime HCD, Knutsford, Cheshire, UK., Santana IR; Prime HCD, Knutsford, Cheshire, UK. |
